Osteoarthritis Is Not Just Wear and Tear: Epstein-Barr Virus LMP1 Exploits Genetic Joint Vulnerability to Drive Inflammatory Cartilage Destruction

Osteoarthritis affects over 500 million people worldwide and has been treated as mechanical wear-and-tear for half a century. Here we propose a model that challenges this paradigm: in patients with genetically vulnerable joints, Epstein-Barr virus (EBV) drives inflammatory cartilage destruction from the synovial membrane. The largest OA genome-wide association study to date (1,962,069 individuals, 286 loci) found zero enrichment in immune cells — all associations converge on structural and developmental pathways (GDF5, COL11A1, TGFβ, BMP, WNT). These are the same pathways intersected by EBV's latent membrane protein 1 (LMP1) via constitutive NF-κB activation. Transcriptomic analysis of synovial membrane from two independent cohorts (GSE89408: 22 OA + 27 normal; GSE283079: 35 OA + 5 controls) reveals massive enrichment of LMP1/NF-κB target genes: 89 of 177 (50.3%) significantly upregulated (Z = 7.18, p < 1e-6). Cartilage-degrading MMPs are elevated 17-25 fold. 60% of OA patients show LMP1 damage scores above the 95th percentile of healthy controls. The virus does not infect cartilage — it destroys it from the adjacent synovial membrane. The model explains why tocilizumab (anti-IL6) and lutikizumab (anti-IL1) failed in OA clinical trials: blocking a single cytokine cannot stop NF-κB from simultaneously driving ten downstream pathways. It predicts that rituximab (anti-CD20), by eliminating EBV-harboring B cells, should succeed where anti-cytokine therapy failed.